Clinical Trials Sponsored by Alexion Pharmaceuticals

Total 19685 results

Alexion

No longer available

Early Access Program for ALXN1840 in Patients With Wilson Disease

Wilson Disease
Alexion

Active, not recruiting

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Italy, Canada, Korea, Republic of, New Zealand, Spain, Turkey
Alexion

Completed

ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Belgium, France, Italy, Japan, Spain, Taiwan, United Kingdom, United States, Canada, Czechia, Germany, Sweden, Singapore, Korea, Republic of, Russian Federation, Austria, Poland, Argentina, Australia, Brazil, Estonia, Malaysia, Mexico, Thaila... and more
Alexion

Completed

A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

France, United Kingdom, Norway, Russian Federation, Netherlands, United States
Alexion

Completed

An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

Atypical Hemolytic-Uremic Syndrome

United Kingdom, United States, France, Italy, Germany, Spain, Belgium
Alexion

Approved for marketing

The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol (EMBRACE)

Hemoglobinuria, Paroxysmal

United States
Alexion

Terminated

Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.

Chronic Hepatitis B
Alexion

Completed

Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma

Allergic Asthma

Canada
Portola Pharmaceuticals
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

Germany
University of Roma La Sapienza
Alexion Pharmaceuticals

Recruiting

Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease (NAFLD LAL)

Non-Alcoholic Fatty Liver Disease

Italy
Yale University
Alexion Pharmaceuticals; Ochsner Health System

Withdrawn

Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation

End Stage Liver Disease

United States
Lawson Health Research Institute
Alexion Pharmaceuticals, Inc.

Active, not recruiting

Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS

Transient Ischemic Attack | Paroxysmal Nocturnal Hemoglobinuria | Cerebral Vein Thrombosis | Embolic Stroke of Undetermined Source

Canada
Cedars-Sinai Medical Center
Alexion Pharmaceuticals, Inc.

Terminated

Complement Regulation to Undo Systemic Harm in Preeclampsia (CRUSH)

Pregnancy Related | Preeclampsia | HELLP Syndrome | Severe Preeclampsia | HELLP | Complement Regulatory Factor Defect | PNH | Eculizumab | HELLP Syndrome Second Trimester | AHUS | Complement Abnormality | HELLP Syndrome Third Trimester

United States
Dr. Lothar Seefried
Alexion Pharmaceuticals

Completed

Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia (EmPATHY)

Hypophosphatasia

Germany
Mario Negri Institute for Pharmacological Research
Alexion Pharmaceuticals

Completed

Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study

IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative Glomerulonephritis

Italy
Alexion
Celerion

Completed

Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants

Healthy

United Kingdom
Alexion Pharmaceuticals
CTI Clinical Trial and Consulting Services

Completed

Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

Delayed Graft Function

France, Germany, Italy, Spain, United States, Canada, Brazil, Australia, Czechia
Alexion Pharmaceuticals, Inc.
Eidos Therapeutics, a BridgeBio company

Active, not recruiting

A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

Symptomatic Transthyretin Amyloid Cardiomyopathy

Japan
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

Hepatitis C

United States, Belgium
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

Human Immunodeficiency Virus (HIV)-1 Infection

United States, Spain, Germany, Dominican Republic
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection

Hepatitis B, Chronic

Bulgaria, Former Yugoslavia
AZ Delta
Alexion

Completed

Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones

Thrombosis | PNH

Belgium
University of Texas Southwestern Medical Center
Alexion Pharmaceuticals, Inc.

Not yet recruiting

Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder (AMAZE)

Neuromyelitis Optica
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

HIV Infections

United States, Puerto Rico
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants

Hepatitis C, Chronic

United States, Canada
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment

HIV Infections

United States
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants

Chronic Hepatitis C Infection

United States
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation (Resistance)

HIV Infections

United States
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria

New Zealand, Korea, Republic of, Italy
Alexion
Achillion, a wholly owned subsidiary of Alexion

Terminated

Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B

Chronic Hepatitis B

United States, Canada, China
Alexion
Syneos Health

Recruiting

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Atypical Hemolytic-Uremic Syndrome

France, Germany, Israel, Italy, United Kingdom, Canada, United States, Australia, Belgium, Denmark, Korea, Republic of, Poland, Russian Federation, Spain, Taiwan
Philip J. Rosenfeld, MD, PhD
Alexion Pharmaceuticals

Completed

Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) (COMPLETE)

Age-Related Macular Degeneration

United States
Alios Biopharma Inc.
Alexion

Completed

A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers

Chronic Hepatitis C

France
Lexicon Pharmaceuticals
Sanofi; Juvenile Diabetes Research Foundation

Completed

Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C

Type 1 Diabetes Mellitus

United States
Fundación Grupo de Investigación en Cuidados Intensivos...
Alexion Pharmaceuticals

Unknown

Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy

Hemolytic-Uremic Syndrome

Colombia
Fundación Grupo de Investigación en Cuidados Intensivos...
Alexion Pharmaceuticals

Unknown

Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series

Pregnancy | Atypical Hemolytic Uremic Syndrome

Colombia
Heeger, Peter, M.D.
Icahn School of Medicine at Mount Sinai; Alexion Pharmaceuticals

Terminated

Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation

Kidney Transplantation | Delayed Graft Function | Complement Activity

United States
Emory University
National Cancer Institute (NCI); Lexicon Pharmaceuticals

Active, not recruiting

Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Recurrent Pancreatic Adenocarcinoma

United States
Andrew Hendifar, MD
Lexicon Pharmaceuticals

Withdrawn

Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain

Pancreatic Cancer | Neuroendocrine Tumors | Cachexia; Cancer
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Acesion Pharma

Recruiting

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study With AP31969

Healthy Volunteers

Netherlands
Acesion Pharma

Completed

A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)

Atrial Fibrillation

Denmark, Hungary
Bexion Pharmaceuticals, Inc.
CTI Clinical Trial and Consulting Services

Terminated

A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors (KOURAGE)

Neoplasms

United States
University Medical Center Groningen
Juvenile Diabetes Research Foundation; Lexicon Pharmaceuticals

Not yet recruiting

Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation (ASPIRE)

Type 1 Diabetes Mellitus With Diabetic Nephropathy

Netherlands, United States, Canada, Denmark, Finland
Bexion Pharmaceuticals, Inc.
CTI Clinical Trial and Consulting Services

Enrolling by invitation

Continued Treatment for Participants Enrolled in Studies of BXQ-350 (ETERNITI)

Neoplasms

United States
Bexion Pharmaceuticals, Inc.
CTI Clinical Trial and Consulting Services

Recruiting

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients (RETRO)

Chemotherapy-induced Peripheral Neuropathy | Neuropathy;Peripheral

United States
Bexion Pharmaceuticals, Inc.
CTI Clinical Trial and Consulting Services

Recruiting

A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) (KONQUER)

Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant

United States
Bexion Pharmaceuticals, Inc.
CTI Clinical Trial and Consulting Services

Completed

Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors

Neoplasms

United States

Clinical Trials Sponsored by Alexion Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations